• Orexo entered a research collaboration with SVF Vaccines to explore stable powder-based LNP-mRNA vaccines using its AmorphOX drug delivery technology.
• The study will test whether spray drying preserves lipid nanoparticle integrity and mRNA activity.
• Positive results could support easier storage and distribution, with potential development toward needle-free intranasal vaccination.
• Initial feasibility results will guide subsequent development and potential expansion of the collaboration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orexo AB published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.